Skip to main navigation Skip to search Skip to main content

Biophysical characterization of GCN2 kinase
: Linking function and structure for drug design

  • Vanesa Vinciauskaite

Student thesis: Doctoral Thesis › Doctor of Philosophy

Abstract

The Integrated Stress Response is a key cell signalling pathway to retain protein homeostasis – proteostasis – within cells upon cellular stress. One of such stresses is the amino acid starvation, where the accumulation of uncharged tRNA promotes eIF2a phosphorylation by GCN2. This response promotes cellular recovery from stress, and induces cell proliferation, angiogenesis. However, in cancer cells, this mechanism is hijacked, where GCN2 is hyperactivated, and tumour growth is promoted. In this thesis, by applying biochemical techniques alongside two prominent structural biology techniques – Cryo-EM and HDX-MS, I have investigated the regulation of GCN2 activation.

Firstly, I investigated the intrinsic properties of GCN2 and how GCN2 is activated by tRNA. By determining the phosphorylation sites on GCN2 and the heterogeneity of GCN2, I describe novel phosphorylation sites. Additionally, the activation of GCN2 by tRNA is described. This leads to an understanding how GCN2 activity is potentially modulated in stressed cells.

Secondly, I researched how GCN2 activity is modulated by small molecules and single domain antibodies. As GCN2 is hyperactivated in cancer cells, I studied how GCN2 activity can be inhibited by an ATP-competitive inhibitor AZD1775 that interacts with GCN2 in an off-target manner and can activate GCN2 at low drug concentrations. As most compounds targeting GCN2 bind the kinase domain, I researched single domain antibodies as an alternative way to target GCN2 to observe inhibitory effects. This serves as an alternative approach to targeting kinases, specifically GCN2, as there is growing interest in GCN2 as a druggable target.

Lastly, I further expand on the research on GCN2 structure. I further describe the progress made and issues faced in obtaining a 3D model of fulllength GCN2 with Cryo-EM, and what steps are required to be taken further. As well as I describe the novel structural rearrangements GCN2 undergoes upon the binding of AZD1775, and describe the epitopes of GCN2, upon which NB14 and NB19 act. This further enables research of GCN2 inhibitors for clinical use.
Date of Award2026
Original languageEnglish
Awarding Institution
  • University of Dundee
SponsorsAstraZeneca
SupervisorGlenn Masson (Supervisor) & Adrian Saurin (Supervisor)

Cite this

'